International application No.

PCT/SE 2005/000411

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07D 401/12, C07D 413/12, C07D 417/12, A61K 31/454, A61K 31/445, A61P 3/04, A61P 25/00
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D, A61K, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE.DK.FI.NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, se arch terms used)

EPO-INTERNAL, STN-CAPLUS, WPI DATA, PAJ C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
Х	GB 2373186 A (ASTRAZENECA AB), 18 Sept 2002 (18.09.2002), RN 479555-54-9, RN 499555-61-8	1-35	

1-35 EP 1389616 A1 (MITSUBISHI PHARMA CORPORATION), X 18 February 2004 (18.02.2004), formula I 1 - 35WO 02066460 A1 (ASTRAZENECA AB), 29 August 2002 X (29.08.2002), formulas I-IV

WO 0114333 A1 (ASTRAZENECA UK LIMITED), 1-35 Х 1 March 2001 (01.03.2001), formulas I-XIV

	<u> </u>					
X	Further documents are listed in the continuation of Box	. C.	See patent family annex.			
*	Special categories of cited documents:	"T"	later document published after the international filing date or priority			
"A"	document defining the general state of the art which is not considered to be of particular relevance		date and not in conflict with the application but cited to understand the principle or theory underlying the invention			
"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive			
"L"	cited to establish the publication date of another citation or other special reason (as specified)		step when the document is taken alone			
			document of particular relevance: the claimed invention cannot be			
"O"			considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art			
"P"	document published prior to the international filing date but later than the priority date claimed	"&"	document member of the same patent family			
Date	e of the actual completion of the international search	Date	of mailing of the international search report			
6	July 2005		1 2 -07- 2005			

Authorized officer

Fernando Farieta/EÖ Telephone No. +46 8 782 25 00

Form PCT/ISA/210 (second sheet) (April 2005)

Name and mailing address of the ISA/

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Swedish Patent Office

International application No. PCT/SE 2005/000411

C (Continu	ation). DOCUMENTS CONSIDERED TO BE RELEVANT	
Category*	Citation of document, with indication, where appropriate, of the relevan	nt passages Relevant to claim No
A	File EPODOC/EPO, TAISHO PHARMA CO LTD et al: "Chemokine receptor antagonist", formula I & WO,A1,03104198, 20031218	1-35
A	File EPODOC/EPO, BANYU PHARMA CO LTD et al: "Novel piperidine derivatives", formula I & WO,A1,0053600, 20000914	1-35
A	 WO 9938514 A1 (MERCK & CO., INC.), 5 August 199 (05.08.1999), formula I	99 1-35
A	 WO 03080574 A1 (ASTRAZENECA AB), 2 October 2003 (02.10.2003), formula I	3 1-35
A	WO 03106452 A2 (MILLENNIUM PHARMACEUTICALS, INC 24 December 2003 (24.12.2003), schemes I-VI	
orm PCT/Is	SA/2.10 (continuation of second sheet) (April 2005)	

International application No. PCT/SE2005/000411

Box	k No. I	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)			
Thi	This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:				
1.	\boxtimes	Claims Nos.: 34-35 because they relate to subject matter not required to be searched by this Authority, namely:			
	met: exe	ims 34-35 relate to a method of treatment of the human or mal body by surgery or by therapy, as well as diagnostic hods /Rule 39.1(iv). Nevertheless, a search has been cuted for these claims. The search has been based on the eged effects of the compounds.			
2.		Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:			
3.		Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).			
Во	x No.	III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)			
Th	is Inte	rnational Searching Authority found multiple inventions in this international application, as follows:			
1.		As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.			
2.		As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.			
3.		As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:			
4.		No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:			
R	emark	on Protest The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee. The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation. No protest accompanied the payment of additional search fees.			

Information on patent family members

28/05/2005

International application No.

PCT/SE 2005/000411

GB	2373186	A	18/09/2002	AU GB	9401001 0104534		22/04/2002 00/00/0000
 EP	 1389616		 18/02/2004	CA	2445348	 A	07/11/2002
EF	1203010	7.1	10,02,200-	US	20040158071		12/08/2004
				CN	1505626		16/06/2004
				WO	02088111	A	07/11/2002
WO	02066460	A1	29/08/2002	AT	276246	T	15/10/2004
				AU	8431101		22/03/200
				DE	60201259		00/00/000
				EP	1317855		11/06/2003
				EP	1363902	-	26/11/2003
				SE	1363902	T3	00 /00 /000
				GB	0104050	D	00/00/000
				JP	2004518742 20040102483	T	24/06/2004 27/05/2004
				US			
WO	0114333	A1	01/03/2001	AU	6461600		19/03/200
				EP	1212299		12/06/200
				JP	2003507456		25/02/200
				SE	9902987	D 	00/00/000
WO	9938514	A1	05/08/1999	AU	2654399		16/08/199
				CA	2319781		05/08/199
				EP	1052992		22/11/200
				GB	9810890		00/00/000
				JP	2002501898		22/01/200
				US US	6132017 6140349		17/10/200 31/10/200
				US	6423303		23/07/200
				US	6476054		05/11/200
WO	03080574	 A1	02/10/2003	AU	2003216012		00/00/000
MO	03080374	ΛI	02/10/2003	BR	0308592		09/02/200
				CA	2479887		02/10/200
				EP	1406747		14/04/200
				ĒΡ	1490336		29/12/200
				SE	0200919		00/00/000
				US	20040171337	A	02/09/200
WO	03106452	A2	24/12/2003	AU	2003243497		00/00/000
				CA	2488635		24/12/200
				US	20040106645	Α	03/06/200